Prise en charge de l’anémie des patients hémodialysés en France : résultats de l’étude DiaNE à trois ans (DiaNE 2)

Barany, 2007, Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease, Nephrol Dial Transplant, 22, iv10, 10.1093/ndt/gfm161 Valderrabano, 2000, European Best Practice Guidelines 1-4. Evaluating anaemia and initiating treatment, Nephrol Dial Transplant, 15, 8, 10.1093/ndt/15.suppl_4.8 MacDougall, 2000, European Best Practice Guidelines 6-8. Assessing and optimizing iron stores, Nephrol Dial Transplant, 15, 20, 10.1093/ndt/15.suppl_4.20 Jacobs, 2000, European Best Practice Guidelines 5. Target haemoglobin, Nephrol Dial Transplant, 15, 15, 10.1093/ndt/15.suppl_4.15 Pisoni, 2004, Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS), Am J Kidney Dis, 44, 94, 10.1053/j.ajkd.2004.03.023 Kessler, 2009, La prise en charge de l’anémie du patient hémodialysé en France s’améliore-t-elle ? Résultats de l’étude DiaNE, Nephrol Ther, 5, 114, 10.1016/j.nephro.2008.09.002 Locatelli, 2004, Revised European Best Practice Guidelines (EBPG) for the management of anaemia in patients with chronic renal failure, Nephrol Dial Transplant, 19, ii1, 10.1093/ndt/gfh1032 European Medicines Agency (EMEA). Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease. 23 October 2007. Doc Ref EMEA/496188/2007.www.emea.europa.eu. Locatelli, 2009, Anaemia management in patients with chronic kidney disease: a position statement by the anemia working group of European Renal Best Practice (ERBP), Nephrol Dial Transplant, 24, 348, 10.1093/ndt/gfn653 Singh, 2006, Correction of anemia with Epoetin alfa in chronic kidney disease, N Eng J Med, 355, 2085, 10.1056/NEJMoa065485 Drüeke, 2006, Normalization of hemoglobin level in patients with chronic kidney disease and anemia, N Eng J Med, 355, 2071, 10.1056/NEJMoa062276 K/DOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease, 2007 update of haemoglobin target. Am J Kidney Dis 2007; 50(3):471–530. Zocalli, 2008, European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP), Nephrol Dial Transplant, 23, 2162, 10.1093/ndt/gfn238 Rosner, 2008, The mortality risk associated with higher hemoglobin: is the therapy to blame?, Kidney Int, 74, 695, 10.1038/ki.2008.263 Singh, 2009, Resolved: targeting a higher hemoglobin isassociated with greater risk in patients with CKD anemia, J Am Soc Nephrol, 20, 1436, 10.1681/ASN.2009040444 Jacobs, 2000, European Best Practice Guidelines 9-13 Anaemia management, Nephrol Dial Transplant, 15, 32 Portolès, 2008, Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study, Kidney Int, 74, S82, 10.1038/ki.2008.524 Lacson, 2003, Effect of variability in anemia management on haemoglobin outcomes in ESRD, Am J Kidney Dis, 41, 11, 10.1053/ajkd.2003.50030 Fishbane, 2005, Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin, Kidney Int, 68, 1337, 10.1111/j.1523-1755.2005.00532.x Ebben, 2006, Hemoglobin level variability: associations with comorbidity, intercurrent events and hospitalizations, Clin J Am Soc Nephrol, 1, 1205, 10.2215/CJN.01110306 Collins, 2000, Impact of hematocrit on morbidity and mortality, Semin Nephrol, 20, 345 Kalantar-Zadeh, 2009, Hemoglobin variability in anemia of chronic kidney disease, J Am Soc Nephrol, 20, 479, 10.1681/ASN.2007070728 Kessler, 2008, Editorial. À propos de l’article de Gilberte Deray intitulé « Comment optimiser le concept de la variabilité de l’hémoglobine chez le patient dialysé », Nephrol Ther, 4, 547, 10.1016/j.nephro.2008.08.001 Deray, 2008, La variabilité de l’hémoglobine chez le patient dialysé, Nephrol Ther, 4, 549, 10.1016/j.nephro.2008.04.010 Muirhead, 2002, A rationale for an individualized haemoglobin target, Nephrol Dial Transplant, 17, 2, 10.1093/ndt/17.suppl_6.2 Gilbertson, 2008, Hemoglobin level variability: associations with mortality, Clin J Am Soc Nephrol, 3, 133, 10.2215/CJN.01610407 Brunelli, 2008, History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients, Clin J Am Soc Nephrol, 3, 777, 10.2215/CJN.04281007 Topf, 2008, CERA: third-generation erythropoiesis-stimulating agent, Expert Opin Pharmacother, 9, 839, 10.1517/14656566.9.5.839 MacDougall, 2006, Novel strategies for stimulating erythropoiesis and potential treatments for anaemia, Lancet, 368, 947, 10.1016/S0140-6736(06)69120-4 Schmidt, 2009, Methoxy polyethylene glycol-Epoetin bêta: worth waiting for or a novelty worn off?, Expert Opin Pharmacother, 10, 1509, 10.1517/14656560902997982 Fishbane, 2007, What is need to achieve a hemoglobin of 11.0–13.0g/dL in end-stage renal disease, Blood Purif, 25, 53, 10.1159/000096398